Purpose: In the modeling of beam data for proton therapy planning systems, absolute dose measurements are performed utilizing a Bragg peak chamber (BPC), which is a parallel‐plate ionization chamber. The long‐term stability of the BPC is crucial for ensuring accurate absolute dose measurement. The study aims to assess the long‐term stability of the BPC in clinical proton pencil beam scanning delivery.Methods: The long‐term stability evaluation focused on the BPC‐Type 34070 (PTW Freiburg, Germany), utilizing clinical proton scanning beams from December 2022 to November 2023. Monthly investigations were conducted to evaluate the response and cross‐calibration factor of the BPC and a reference chamber, employing the spread‐out Bragg peak (SOBP) field. Additionally, assessments were made regarding the BPC's response to monoenergetic beams, along with an examination of the impact of polarity and ion recombination on the BPC.Results: The response and cross‐calibration factor of the BPC varied up to 1.9% and 1.8%, respectively, while the response of the reference chamber remained within a 0.5% range. The BPC's response to the mono‐energetic beams varied up to 2.0% across all energies, demonstrating similar variation trends in both the SOBP field and mono‐energetic beams. Furthermore, the variations in polarity and ion recombination effect remained stable within a 0.4% range throughout the year. Notably, the reproducibility of the BPC remained high for each measurement conducted, whether for the SOBP field or mono‐energetic beams, with a maximum deviation observed at 0.1%.Conclusions: The response and cross‐calibration factor of the BPC demonstrated significant variations, with maximum changes of 1.9% and 1.8%, respectively. However, the reproducibility of the BPC remained consistently high for each measurement. It is recommended that when conducting absolute dose measurements using a BPC, its response should be compared and corrected against the reference chamber for each measurement.
29 June 2024 in Japanese Journal of Clinical Oncology
Proton beams deposit energy along their path, abruptly stopping and generating various radioactive particles, including positrons, along their trajectory. In comparison with traditional proton beam therapy, scanning proton beam therapy is effective in delivering proton beams to irregularly shaped tumors, reducing excessive radiation exposure to the alimentary tract during the treatment of liver cancer. In this study, we utilized positron emission tomography/computed tomography (PET/CT) imaging to assess the total amount of radiation to the alimentary tract during liver cancer treatment with proton beam therapy, involving the administration of complex irradiation in 13 patients. This approach resulted in the prevention of excess radiation. The planned radiation restraint doses for the colon exhibited a significant correlation with the PET values of the colon (correlation coefficient 0.8384, P = .0003). Likewise, the scheduled radiation restraint doses for the gastroduodenum were correlated with the PET values of the gastroduodenum (correlation coefficient 0.5397, P = .0569). PET/CT conducted after proton beam therapy is useful for evaluating excess radiation in the alimentary tract. Proton beam therapy in liver cancer, assessed via PET/CT, effectively reduced alimentary tract radiation, which is vital for optimizing treatments and preventing excess exposure.
Respiratory-gated proton therapy can mitigate interplay effects between the proton beam and target motion. However, the residual motion of the target within the gating window (GW) may still cause clinically relevant dosimetric variations. This study aimed to evaluate target and normal-tissue doses associated with residual motion within the GW. Eight patients with non-small cell lung cancer were analyzed. For each GW setting, the internal clinical target volume (iCTV) was defined as the union of clinical target volumes (CTVs) within the GW. Maximum residual motion (MRM) was defined as the maximum CTV motion within the GW relative to the 50% phase. Treatment plans were generated for single-field uniform dose (SFUD) and intensity-modulated proton therapy (IMPT). Dynamic 4D dose (D4DD) was calculated, and differences in dose metrics between the treatment plan and D4DD (ΔDM) were evaluated for CTV D95%, D98%, and D2%, and for lungs V20GyE and average dose (AD). Increasing MRM was associated with decreased CTV D95% and D98% and increased CTV D2% for both SFUD and IMPT. When MRM was ≤3 mm, CTV ΔDM remained within ±3%; however, some metrics exceeded 5% when MRM was >5 mm. Lungs ΔAD showed a slight increasing trend with MRM but remained within 0.25%. Lungs ΔV20GyE showed no clear correlation with MRM and varied from -5.7% to 7.1%; however, the values remained within ±3% when MRM was <3 mm. When MRM was <3 mm, ΔDM for both the target and lungs were within ±3%. Therefore, selecting a GW that limits MRM to <3 mm may represent an appropriate criterion for both SFUD and IMPT.
This study aimed to investigate the distribution of thermal neutron fluence generated during proton-beam therapy (PBT) scanning, focusing on neutrons produced within the body using Monte Carlo simulations (MCSs). MCSs used the Particle and Heavy Ion Treatment Code System to define a 35 × 35 × 35 cm3 water phantom, and proton-beam energies ranging from 70.2 to 228.7 MeV were investigated. The MCS results were compared with neutron fluence measurements obtained from gold activation analysis, showing good agreement with a difference of 3.54%. The internal thermal neutron distribution generated by PBT was isotropic around the proton-beam axis, with the Bragg peak depth varying between 3.45 and 31.9 cm, while the thermal neutron peak depth ranged from 5.41 to 15.9 cm. Thermal neutron generation depended on proton-beam energy, irradiated particle count, and depth. Particularly, the peak of the thermal neutron fluence did not occur within the treatment target volume but in a location outside the target, closer to the source. This discrepancy between the Bragg peak and the thermal neutron fluence peak is a key finding of this study. These data are crucial for optimizing beam angles to maximize dose enhancement within the target during clinical applications of neutron capture-enhanced particle therapy.
18 June 2025 in International Journal of Particle Therapy
To develop and validate a novel 3-dimensional quality assurance (QA) method using an X-ray computed tomography-based polymer gel dosimeter (XCT-PGD) and an integrated cone-beam computed tomography (CBCT) system, enabling comprehensive verification of spot positions and isocenter accuracy for proton therapy. A PROBEAT-M1 proton therapy system was used to irradiate an XCT-PGD with spot scanning beams from 4 gantry angles (45°, 180°, 270°, and 315°). Three spot positions, including the isocenter position, were evaluated. Pre- and postirradiation CBCT scans were acquired to determine the spot positions. The accuracy of the proposed method was validated against conventional Winston-Lutz tests and beam delivery log file analysis. Spot positions were analyzed using 3-dimensional visualization of the beam trajectories within the gel dosimeter. The proposed method demonstrated excellent agreement with conventional techniques. The isocenter position determined using our method was within 0.39 mm that from the Winston-Lutz test. Spot position from our method was within 0.37 mm that from log file analysis. Three-dimensional detection using the gel dosimeter enabled simultaneous verification of multiple spot positions and beam trajectories, providing comprehensive spatial information not available through conventional 2-dimensional methods. Combining an XCT-PGD with CBCT provides a robust and comprehensive method for 3-dimensional verification of the accuracy of proton therapy delivery. This novel approach offers advantages over conventional QA techniques by enabling simultaneous evaluation of spot positions and isocenter accuracy while minimizing setup uncertainties. The method is particularly suitable for annual QA and commissioning procedures in proton therapy facilities.